Cabaletta Bio

Cabaletta Bio

Cabaletta Bio

Cabaletta Bio has adapted clinicallyvalidated and FDAapproved CAR T cell technology to target B cellmediated autoimmune diseases with its CAAR T cell technology.
Founded
2017
Raised
$50M
Follow us
Alexa global traffic share
Twitter followers
06 Jan 2019
$50,000,000
Venture capital (Series B)

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies

MedCity News
+1